Drugs / PF-06835375
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03334851 | Nov 2017 → Feb 2022 | rheumatoid arthritis, systemic lupus erythematosus | Pfizer | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05070845 | Feb 2022 → Aug 2028 expected | autoimmune thrombocytopenia | Pfizer | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-06835375 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03334851 ↗ |
| Action | Deplete | “potentially depletes B cells, follicular T helper (Tfh) cells, and circulating Tfh-like (cTfh) cells” PMID 38845046 ↗ Jun 2024 |
| Modality | Monoclonal antibody | “a potent selective afucosyl immunoglobulin G1 antibody targeting C-X-C chemokine receptor type 5 (CXCR5)” PMID 38845046 ↗ Jun 2024 |
| Route | Intravenous | “single doses of intravenous PF-06835375” PMID 38845046 ↗ Jun 2024 |
| Target | CXCR5 | “a potent selective afucosyl immunoglobulin G1 antibody targeting C-X-C chemokine receptor type 5 (CXCR5)” PMID 38845046 ↗ Jun 2024 |